Literature DB >> 25406210

A patient with mosaic neurofibromatosis type 2 presenting with early onset meningioma.

Yoyo Wing-Yiu Chu1, Daniel Ka Leung Cheuk1, Brian Hon Yin Chung1, Naomi L Bowers2, Shau-Yin Ha1, Alan Kwok-Shing Chiang1, Godfrey Chi-Fung Chan1.   

Abstract

A female patient was found to have meningioma when she was 3 years and 11 months old and subtotal excision was performed. The residual tumour recurred 3 months after the first excision, and again 11 months after the second one. She was also found to have subcutaneous neurofibroma. However, her clinical features did not fulfil the diagnostic criteria for neurofibromatosis type 2 (NF2), and her family history was unremarkable. Considering that primary meningioma is extremely rare in the paediatric population, the diagnosis of NF2 was considered. It was thought that this might have an impact on her subsequent management. Genetic testing on blood DNA for NF2 was arranged, and the results confirmed that she had mosaic deletion of the promoter to exon 16 of NF2. With uncertainty of whether NF2 mutations are also present in other tissues, vigilant follow-up for other NF2-related complications would be required in the future. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Year:  2014        PMID: 25406210      PMCID: PMC4244520          DOI: 10.1136/bcr-2014-203919

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  15 in total

1.  Atypical molecular background of glioblastoma and meningioma developed in a patient with Li-Fraumeni syndrome.

Authors:  Piotr Rieske; Magdalena Zakrzewska; Wojciech Biernat; Jacek Bartkowiak; Arthur Zimmermann; Paweł Piotr Liberski
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

Review 2.  A genomic view of mosaicism and human disease.

Authors:  Leslie G Biesecker; Nancy B Spinner
Journal:  Nat Rev Genet       Date:  2013-05       Impact factor: 53.242

3.  Meningioma showing VHL gene inactivation in a patient with von Hippel-Lindau disease.

Authors:  H Kanno; I Yamamoto; M Yoshida; H Kitamura
Journal:  Neurology       Date:  2003-04-08       Impact factor: 9.910

4.  Evaluation of clinical diagnostic criteria for neurofibromatosis 2.

Authors:  M E Baser; J M Friedman; A J Wallace; R T Ramsden; H Joe; D G R Evans
Journal:  Neurology       Date:  2002-12-10       Impact factor: 9.910

Review 5.  Pediatric meningioma: current approaches and future direction.

Authors:  Rishi S Kotecha; Reimar C Junckerstorff; Sharon Lee; Catherine H Cole; Nicholas G Gottardo
Journal:  J Neurooncol       Date:  2011-01-04       Impact factor: 4.130

6.  Earliest clinical manifestations and natural history of neurofibromatosis type 2 (NF2) in childhood: a study of 24 patients.

Authors:  M Ruggieri; P Iannetti; A Polizzi; I La Mantia; A Spalice; O Giliberto; N Platania; A L Gabriele; V Albanese; L Pavone
Journal:  Neuropediatrics       Date:  2005-02       Impact factor: 1.947

7.  Central nervous system meningiomas in the first two decades of life: a clinicopathological analysis of 87 patients.

Authors:  Elisabeth J Rushing; Cara Olsen; Hernando Mena; Maria-Eugenia Rueda; Youn-Soo Lee; Robert F Keating; Roger J Packer; Mariarita Santi
Journal:  J Neurosurg       Date:  2005-12       Impact factor: 5.115

8.  Predictors of the risk of mortality in neurofibromatosis 2.

Authors:  Michael E Baser; J M Friedman; Dana Aeschliman; Harry Joe; Andrew J Wallace; Richard T Ramsden; D Gareth R Evans
Journal:  Am J Hum Genet       Date:  2002-08-22       Impact factor: 11.025

9.  Childhood and adolescent meningiomas: a report of 38 cases and review of literature.

Authors:  G Menon; S Nair; J Sudhir; B R M Rao; A Mathew; B Bahuleyan
Journal:  Acta Neurochir (Wien)       Date:  2009-02-24       Impact factor: 2.216

10.  Childhood and juvenile meningiomas.

Authors:  Xing Gao; Rong Zhang; Ying Mao; Yin Wang
Journal:  Childs Nerv Syst       Date:  2009-07-30       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.